1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. Kidney Int Suppl. 2017; 7: S1-59.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4, Suppl 3): S1-201.
3. Karlovich N.V. Vtorichnyi giperparatireoz pri khronicheskoi bolezni pochek: monografiya // N.V. Karlovich N.V., T.V.Mokhort; UO BGMU. - Minsk: 2021. - 177 s.: tabl., il. - Bibliogr.: 339 nazv.
4. Bello AK, Levin A, Lunney M, et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019; 367: l5873.
5. Horl W.H. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004; 19 (5): 2-8.
6. Joy M.S. Outcomes of secondary hyperparathyroidism in chronic kidney disease and direct costs of treatment. J Manag Care Pharm. 2007; 13(5): 397-411.
7. Moe S., Drueke T., Lameire N., Eknoyan G. Chronic kidney disease - mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007; 14(1): 3-12.
8. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl. 2009; 113: S1-130.
9. Shigematsu T et al. Target range of PTH in ESRD patients. Clin Calcium. - 2002; 12(12): 1665-1673.
10. Pazianas M., Miller P.D. Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in Its managemen. J Bone Metab. 2020; 27(1): 1-13.
11. Phelps K.R., Mason D.L. An examination of multiple explanations for secondary hyperparathyroidism. Clin Nephrol. 2020; 94(2):70-77.
12. Karlovich N.V. Vtorichnyi giperparatireoz, defitsit vitamina D3 i narusheniya fosforno-kal'tsievogo obmena u patsientov s razlichnymi stadiyami khronicheskoi bolezni pochek. Lechebnoe delo. 2016; 5 (51): 35 - 39.
13. Karlovich N.V., Spiridonova O.S., Sazonova E.G., Mokhort T.V. Opredelenie referentnogo intervala paratgormona u patsientov s razlichnymi stadiyami khronicheskoi bolezni pochek. Vestsі Natsyyanal'nai akademіі navuk Belarusі. Seryya medytsynskіkh navuk. 2020; 19 (2): 186-194.
14. Karlovich N.V., Spiridonova O.S., Mokhort T.V., Sazonova E.G., Valovik O.E. Metod diagnostiki vtorichnogo giperparatireoza / Instruktsiya po primeneniyu. № 147-1220, 16.12.2020
15. Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017; 9(4): 328.
16. Metzger M, Houillier P, Gauci C, et al. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold. J Clin Endocrinol Metab. 2013; 98 (7): 2922-8.
17. Obi Y, Hamano T, Isaka Y. Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers. 2015; Epub 2015 Mar 26.
18. Review. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96 (7): 1911-1930.
19. Amrein, K. et al. Vitamin D deficiency 2.0: an update on the current status worldwide. European Journal of Clinical Nutrition. 2020; 74 (11): 1498-1513.
20. Pigarova E.A. i dr. Klinicheskie rekomendatsii Rossiiskoi assotsiatsii endokrinologov po diagnostike, lecheniyu i profilaktike defitsita vitamina D u vzroslykh. Probl. endokr. 2016; 4: 60-84.
21. Karlovich N.V., Marchuk S.I., Sazonova E.G., Mokhort T.V. Polimorfizmy gena retseptora vitamina D, defitsit vitamina D i vtorichnyi giperparatireoz u patsientov s khronicheskoi bolezn'yu pochek. Retsept. 2020; 23 (5): 54-62.
22. Karlovich N.V., Mokhort T.V., Sazonova E.G., Valovik O.E., Yurenya E.V. Metod lecheniya nedostatochnosti vitamina D / Instruktsiya po primeneniyu. № 154-1220, 16.12.2020
23. Young E.W. et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44 (Suppl 2): 34-38.
24. Tentori F., Wang M., Bieber B.A. et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015; 10(1): 98-109.
25. Karlovich N.V. Narusheniya sekretsii paratgormona i sostoyanie fosforno-kal'tsievogo obmena u patsientov s terminal'noi stadiei khronicheskoi bolezni pochek. Meditsinskii zhurnal. 2009; 2: 72-75.
26. Pasieka J.L., Parsons L.L., Demeure M.J., et al. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg. 2002; 26(8): 942-9.
27. Pisoni R.L. et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006; 21(12): 3495-3505.
28. Rivet J. et al. Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. Arch Dermatol. 2006; 142(7): 900-906.
29. Karlovich N.V. Otsenka znachimosti klinicheskikh simptomov v diagnostike vtorichnogo giperparatireoza. Lechebnoe delo. 2020; 72 (2): 57-62.
30. Karlovich N.V. Vozmozhnosti vizualizatsii parashchitovidnykh zhelez. Meditsinskie novosti. 2009; 3: 12-16.
31. Petranović Ovčariček P, Giovanella L, Carrió Gasset I, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021; 48(9): 2801-2822.
32. Karlovich N.V., Moiseeva V.M., Tolkachev Yu.V., i dr. Rezul'taty vizualizatsii parashchitovidnykh zhelez u patsientov s vtorichnym giperparatireozom na fone terminal'noi stadii khronicheskoi bolezni pochek. Ars medica (Iskusstvo meditsiny). 2011; 10 (46): 74-79.
33. Moe S., Drueke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953.
34. Miller P.D. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med. 2009; 76 (12): 715-723.
35. Karlovich N.V., Komissarov K.S., Gromyko V.N., i dr. Pochechnaya osteodistrofiya: sovremennye podkhody k diagnostike i lecheniyu. Meditsinskii zhurnal. 2007; 1 (19): 44-48.
36. Zayour D., Daouk M., Medawar W., et al. Predictors of bone mineral density in patients on hemodialysis. Transplant Proc. 2004; 36(5): 1297-1301.
37. Lacativa P.G., de Mendonca L.M., de Mattos Patricio Filho et al. Risk factors for decreased total body and regional bone mineral density in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Densitom. 2005; 8(3): 352-361.
38. Karlovich N.V., Mokhort T.V. Osteoporoz: osobennosti razvitiya i diagnostiki u patsientov s khronicheskoi bolezn'yu pochek. Meditsinskie novosti. 2008; 4: 23-28.
39. Miller M.A. et al. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 1998; 23(3): 257-266.
40. Karlovich N.V. Vliyanie nekotorykh faktorov na mineral'nuyu plotnost' kosti u patsientov s terminal'noi stadiei khronicheskoi bolezni pochek. Meditsinskii zhurnal. 2013; 4: 73-75.
41. Karlovich N.V. Kompleksnaya otsenka sostoyaniya kostnoi tkani u patsientov s terminal'noi stadiei khronicheskoi bolezni pochek. Zdravookhranenie. 2014; 11:
42. Cozzolino M., Shilov E., Li Z. et al. Pattern of laboratory parameters and management of secondary hyperparathyroidism in countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020; 37(6): 2748-2762.
43. Komissarov K.S., Pilotovich V.S., Gromyko V.N., i dr. Korrektsiya giperfosfatemii u dializnykh bol'nykh. Lechebnoe delo. 2009; 2: 38-41.
44. Karlovich N.V., Komissarov K.S., Sysoeva O.V., i dr. Opyt primeneniya kal'tsitriola dlya korrektsii vtorichnogo giperparatireoza u dializnykh patsientov. Zdravookhranenie. 2008; 9: 76-80.
45. Rodriguez M. et al. The calcium-sensing receptor - a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005; 288 (2): 253-264.
46. Karlovich N.V., Mokhort T.V. Vitamin D, paratgormon i khronicheskaya bolezn' pochek. Lechebnoe delo. 2016; 4 (50): 73 - 80.
47. Karlovich N.V., Sazonova E.G., Valovik O.E., i dr. Opyt primeneniya kolekal'tsiferola dlya korrektsii defitsita vitamina D i vtorichnogo giperparatireoza u patsientov s khronicheskoi bolezn'yu pochek. Lechebnoe delo. 2019; 4(68): 34- 40.
48. Komissarov K.S., Karlovich N.V., Kondratovich V.A., i dr. Paratireoidektomiya kak metod lecheniya vtorichnogo giperparatireoza u dializnykh bol'nykh. Meditsina. 2009; 2: 88-91.
49. Miller P.D. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial. 2007; 20(3): 186-190.
50. Karlovich N., Mokhort T., Sysoeva O., i dr. Opyt primeneniya ibandronovoi kisloty dlya korrektsii osteoporoza u dializnykh patsientov s vtorichnym giperparatireozom. Zdravookhranenie. 2009; 6: 75-80.
51. Karlovich N.V. Rezul'taty dinamicheskogo kogortnogo nablyudeniya funktsii parashchitovidnykh zhelez u patsientov s vtorichnym giperparatireozom. Mezhdunarodnyi endokrinologicheskii zhurnal. 2015; 1 (65): 13-18.
Email this article 